CRISPR Therapeutics (NASDAQ:CRSP) Receives “Market Outperform” Rating from JMP Securities

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $86.00 target price on the stock. JMP Securities’ price objective would indicate a potential upside of 112.98% from the company’s previous close.

CRSP has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Barclays reduced their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $77.93.

CRISPR Therapeutics Trading Down 1.7 %

CRISPR Therapeutics stock opened at $40.38 on Friday. The stock has a 50-day moving average price of $48.57 and a two-hundred day moving average price of $50.89. CRISPR Therapeutics has a 12 month low of $39.80 and a 12 month high of $91.10. The company has a market capitalization of $3.45 billion, a PE ratio of -14.27 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the firm posted ($1.41) earnings per share. As a group, analysts predict that CRISPR Therapeutics will post -5.13 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,382 shares of company stock worth $2,744,179. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently modified their holdings of the company. Franklin Resources Inc. increased its position in shares of CRISPR Therapeutics by 12.7% during the third quarter. Franklin Resources Inc. now owns 7,097 shares of the company’s stock valued at $339,000 after acquiring an additional 800 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter valued at $40,000. Sanctuary Advisors LLC increased its position in shares of CRISPR Therapeutics by 17.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company’s stock valued at $398,000 after purchasing an additional 1,258 shares during the last quarter. Sunbelt Securities Inc. raised its stake in shares of CRISPR Therapeutics by 11.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock worth $139,000 after purchasing an additional 300 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after buying an additional 35,196 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.